TACR1 and neoplasm: Combined treatment with CaMKII and NK1R inhibitors not only markedly suppressed GSC viability and tumorsphere formation but also effectively inhibited GSC-derived tumor growth in comparison with a single-compound treatment in an in vivo model of tumorigenesis.